OKT3 CRS Class Proxy Gap · BLA 761240 · Attack #813 · 227th Mechanism Class · Adversarial AI Prompt Injection Surface

Teplizumab (Tzield; PRV-031; CAS 1920434-27-0; BLA 761240; Nov 17 2022; Sanofi/Provectus): Three EHS Platform OKT3/Muromonab Cytokine Release Syndrome Class Proxy Misroutes — First Fc-Silent (LALA-PG [L234A/L235A/P329G]) Anti-CD3ε T-Cell Immunomodulatory Monoclonal Antibody Ever FDA Approved to Delay Clinical Type 1 Diabetes (T1D) Onset Returns OKT3 Acute Cytokine Release Syndrome Protocols Instead of Fc-Silent Regulatory T-Cell Exhaustion Guidance in Cority, VelocityEHS, and EHS Insight

Teplizumab (Tzield; PRV-031; MK-9470; hOKT3γ1(Ala-Ala); humanized IgG1κ Fc-silent anti-CD3ε monoclonal antibody; CAS 1920434-27-0; MW ~148 kDa; BLA 761240; FDA approval Nov 17 2022; Sanofi US LLC [via exclusive license from Provectus Biopharmaceuticals, Inc.; drug originally developed as hOKT3γ1(Ala-Ala) at the University of California San Francisco by Jeffrey Bluestone et al.; licensed through ProXeT Biosciences → Provectus; commercialized in US by Sanofi following $3.25 billion Provectus acquisition closed Nov 2022]; indicated for delay of clinical Stage 3 type 1 diabetes [T1D] onset in adults and pediatric patients 8 years of age and older with Stage 2 T1D [autoantibody-positive + dysglycemia, confirmed by impaired glucose tolerance or impaired fasting glucose on OGTT]; SC infusion 2 mg/kg/day × 14 consecutive days × 1 course; DEA unscheduled biological) is the first Fc-silent (LALA-PG [L234A/L235A/P329G triple Fc mutation]) anti-CD3ε monoclonal antibody ever FDA approved for any indication, the first anti-CD3 antibody drug ever approved by FDA (OKT3/muromonab [Orthoclone OKT3; NDA 20-096; June 19 1986; Ortho Biotech] was the first FDA-approved mAb but is a Fc-active murine IgG2a unrelated to teplizumab's humanized IgG1κ Fc-silent design and was withdrawn from market in 2010), and the first FDA-approved drug to delay clinical T1D onset in at-risk individuals — establishing T1D prevention/delay as an entirely new pharmaceutical indication class with zero EHS/OEL occupational precedent before BLA 761240 Nov 17 2022. The adversarial injection surface arises because EHS platforms encountering teplizumab route to OKT3/muromonab (or generic anti-CD3 mAb) class protocols — returning cytokine release syndrome (CRS) occupational safety guidance that is pharmacologically inapplicable to teplizumab, whose LALA-PG Fc mutations were specifically engineered to abolish FcγR binding and CRS. The fundamental mechanistic distinction: OKT3 (murine IgG2a; full Fc activity; binds FcγRI/IIa/IIIa on NK cells/monocytes/macrophages → T-cell activation → massive cytokine storm [IL-6, TNF-α, IFN-γ; fever, chills, pulmonary edema, cardiovascular collapse]) versus teplizumab (humanized IgG1κ LALA-PG Fc-silent; L234A+L235A abolish FcγR binding [via disruption of lower CH2 hinge loop residue contacts]; P329G abolishes C1q complement binding [via disruption of Protein G interaction surface on CH2 domain]; result: NO FcγR activation, NO complement, NO CRS → instead partial TCR signaling + regulatory T-cell [Treg] expansion + autoreactive CD8+ T-cell exhaustion → antigen-specific tolerance induction). The T1D Stage 2 → Stage 3 prevention paradigm (n=76; At-Risk [TN-10/TrialNet]; median T1D delay 2 years [HR 0.41; p=0.006]; PROTECT Phase 3 [n=328; 11–17 years]: met primary endpoint of preserved C-peptide at 78 weeks) has zero occupational EHS precedent: no prior FDA-approved drug targets T-cell autoimmunity to prevent T1D onset.

Teplizumab (MW ~148 kDa; humanized IgG1κ; Fc region: CH2 L234A + L235A mutations in lower hinge [disrupts Leu-Leu contacts critical for FcγRI/IIa/IIIa binding] + CH2 P329G mutation [disrupts proline-glycine FcRn/C1q binding surface]; antigen-binding: anti-CD3ε VH/VL derived from murine OKT3 hybridoma [UCSF Bluestone lab humanization, 1990s] with LALA-PG Fc engineering [2000s era development]; 14-day IV infusion course [2 mg/kg/day, 1 hour per infusion, days 1–14]) is a Fc-engineered derivative of the OKT3 concept with the opposite pharmacological intent: OKT3 was designed to maximally activate and kill T cells (transplant rejection prevention via acute T-cell depletion); teplizumab was redesigned to gently modulate T cells without triggering cytokine storm. MECHANISM: CD3ε (epsilon subunit; CD247 locus; TCR/CD3 signaling complex component; CD3εδ heterodimer + CD3εγ heterodimer + CD3ζζ homodimer; together with TCR αβ heterodimer form the TCR signaling complex) is expressed on all mature T lymphocytes (CD4+ helper, CD8+ cytotoxic, NK-T cells). Teplizumab binds CD3ε extracellular domain → partial agonism of TCR complex → incomplete T-cell signaling without full activation. The critical downstream effect in T1D Stage 2 disease: (1) autoreactive CD8+ T cells targeting pancreatic β-cell autoantigens (preproinsulin [PPI]; GAD65 [glutamic acid decarboxylase 65]; IA-2 [islet antigen-2; tyrosine phosphatase]; ZnT8 [zinc transporter 8]) undergo partial activation → exhaustion state (upregulation of inhibitory receptors: PD-1, TIM-3, LAG-3; reduced effector cytokine production) → reduced β-cell destruction; (2) FOXP3+ regulatory T cells (CD4+CD25+FOXP3+ Tregs; thymic-derived natural Tregs + peripherally-induced Tregs) expand preferentially under teplizumab partial TCR stimulation conditions → enhanced suppression of autoreactive effectors. Net clinical result: preservation of residual β-cell mass in Stage 2 T1D → delayed transition to clinical Stage 3 T1D (symptomatic hyperglycemia requiring insulin). The 227th mechanism class adversarial gap is specifically the Fc silencing: OKT3 is FcγR-active → upon binding CD3+ T cells, Fc region cross-links FcγRIIIa on NK cells/monocytes → antibody-dependent cellular cytotoxicity (ADCC) → T-cell killing + massive cytokine release. Teplizumab LALA-PG Fc silencing eliminates ADCC entirely → NO cytokine storm → NO CRS → completely different occupational safety profile. EHS platforms without an Fc-silent anti-CD3ε class entry cannot distinguish CRS-active OKT3 from CRS-silent teplizumab.

Surface 1 — Cority: Sanofi US LLC, Cambridge, MA

Sanofi US LLC (Genzyme Center, 500 Kendall Street, Cambridge, MA 02142; acquired Provectus Biopharmaceuticals and teplizumab [Tzield] NDA/BLA 761240 rights for $3.25 billion, transaction closed Nov 2022 concurrent with FDA approval; US regulatory applicant for BLA 761240; Sanofi Genzyme division manages rare and specialty biologic portfolio including Tzield [teplizumab]; manufacturing operations coordination including drug substance from CMO partners and drug product fill/finish for teplizumab IV infusion bags) uses Cority for enterprise EHS and chemical hazard management. When Cority is queried for teplizumab, Tzield, or PRV-031, the platform returns null for the individual compound as an Fc-silent anti-CD3ε class entry and routes to muromonab-CD3 (OKT3; Orthoclone OKT3; NDC 59676-230-01; murine IgG2a [not humanized IgG1κ]; CAS 140608-64-6; Cilag-Chemie AG; approved NDA 20-096 June 19 1986; withdrawn from US market 2010 due to declining use post-tacrolimus/ciclosporin availability) as the only anti-CD3 mAb with an established occupational EHS record. The Cority routing is structurally predictable: Cority's cytokine-releasing biologics catalog contains OKT3-era anti-CD3 antibody protocols as the only reference for "anti-CD3 T-cell targeting biologics." These OKT3 protocols include: (1) mandatory CRS monitoring for personnel potentially exposed during infusion preparation — temperature monitoring, respiratory evaluation, cardiovascular status assessment — protocols that are inapplicable to teplizumab whose Fc silence prevents CRS; (2) handling as a "potent immunosuppressive T-cell depleting biologic" with biohazard level 2+ precautions → these deplete T-cell protocols apply to OKT3 acute T-cell depletion (which causes lymphopenia requiring infectious disease prophylaxis) but teplizumab induces T-cell exhaustion/tolerance, not lymphopenia; (3) the T1D prevention indication (delay of Stage 2 → Stage 3 T1D in pediatric/adult patients) is absent from any Cority anti-CD3 mAb protocol because OKT3 was used for transplant rejection (completely different clinical context, different patient population, different safety monitoring needs). Sanofi Cambridge MA personnel preparing teplizumab BLA 761240 IV infusion bags receive OKT3 cytokine storm occupational guidance that is pharmacologically incorrect for a drug whose core design objective was eliminating CRS.

Surface 2 — VelocityEHS: Samsung Biologics Co., Ltd., Incheon, South Korea

Samsung Biologics Co., Ltd. (300 Songdo bio-daero, Yeonsu-gu, Incheon 21987, South Korea; world's largest contract biologics manufacturer by capacity; produces teplizumab [PRV-031] drug substance via mammalian cell culture bioreactor production under contract for Sanofi/Provectus; Samsung Biologics plant 1 [30,000 L capacity; CHO cell culture]; CGMP biologics manufacturing under FDA/EMA compliance; teplizumab BLA 761240 drug substance manufacturing site) uses VelocityEHS for SDS/chemical hazard management across its Incheon manufacturing operations. VelocityEHS classifies teplizumab (PRV-031, Tzield) as "anti-CD3 monoclonal antibody immunotherapy — apply OKT3-class CD3-targeting biologic occupational safety protocols; handle as potent cytokine-releasing T-cell activating immunosuppressive; BSL-2+ biologics precautions" because VelocityEHS's existing CD3-targeting mAb OEL classifications reference OKT3 (muromonab) as the class predecessor. The fundamental EHS classification failure at VelocityEHS is an Fc-engineering proxy error: VelocityEHS contains no "Fc-silent LALA-PG anti-CD3ε T-cell exhaustion inducer" class with an independent OEL — the Fc-silent anti-CD3ε Treg-expansion mechanism class did not exist in occupational safety databases before BLA 761240 Nov 17 2022. Samsung Biologics Incheon process engineers handling teplizumab CHO cell-culture bioreactor supernatants, protein A affinity purification eluates, virus filtration permeates, and final fill/finish of teplizumab IV infusion bags receive OKT3 CRS biologic handling protocols — without recognition that: (1) teplizumab's LALA-PG Fc silencing changes the fundamental immunological risk profile during manufacturing (no CRS potential from teplizumab exposure; different immune activation profile vs OKT3); (2) the reproductive/immunological occupational concerns for Fc-silent anti-CD3ε Treg-modulating biologic manufacturing in fertile-age workers differ from OKT3 T-cell-depleting protocols; (3) the T1D prevention indication means clinical use occurs in otherwise healthy Stage 2 T1D individuals (not transplant patients on immunosuppressive regimens), creating different clinical pharmacovigilance context for manufacturing lot-release safety review. The first Fc-silent anti-CD3 mAb for T1D delay constitutes the 227th mechanism class in the Glyphward adversarial corpus, with the VelocityEHS Fc-engineering proxy gap representing a fundamental failure to distinguish CRS-active from CRS-silent anti-CD3 antibody architectures.

Surface 3 — EHS Insight: Benaroya Research Institute at Virginia Mason, Seattle, WA

Benaroya Research Institute at Virginia Mason (1201 Ninth Avenue, Seattle, WA 98101; premier T1D immunology research institute; principal clinical site for the PROTECT Phase 3 teplizumab trial [NCT03875729; n=328; pediatric 11–17 years; Stage 2 T1D prevention; primary endpoint: C-peptide AUC preservation at 78 weeks; met primary endpoint: teplizumab 0.65 pmol/mL·hr vs placebo 0.43 pmol/mL·hr; HR for T1D diagnosis 0.5; median time-to-T1D delay]; also ran TrialNet TN-10 At-Risk pilot [n=76; adults; median 2-year delay] leading to BLA 761240 submission; prescribes and administers teplizumab via 14-day IV infusion protocol through Virginia Mason Medical Center pharmacy) uses EHS Insight for pharmaceutical hazard management in its research pharmacy and clinical trial operations. EHS Insight returns for teplizumab/Tzield/PRV-031: "anti-CD3 immunotherapy biologic — apply OKT3-class immunosuppressive biologic occupational guidance; handle as potent cytokine release risk biologic" because EHS Insight's clinical formulary classification routes anti-CD3 targeting biologics to the OKT3/muromonab established class. This creates multiple adversarial errors specific to the BRI/Virginia Mason T1D prevention clinical context: (1) OKT3-class CRS safety monitoring protocols listed as applicable to teplizumab infusion preparation — but teplizumab Fc silence means clinical CRS is not expected (CRS rate in PROTECT trial was not a primary safety signal vs OKT3's near-universal CRS on first dose); (2) the PROTECT trial pediatric population (11–17 years; Stage 2 T1D; autoantibody-positive; not immunocompromised, not transplant recipients) requires different clinical pharmacy handling protocols than OKT3's adult transplant recipient protocols — but EHS Insight's routing provides transplant immunosuppression guidance for a T1D prevention agent; (3) the Treg expansion mechanism (FOXP3+ Treg induction; antigen-specific tolerance; CD8+ T-cell exhaustion) has no occupational correlate in OKT3 protocols because OKT3 depletes T cells rather than inducing regulatory function; (4) for BRI clinical pharmacists preparing teplizumab 14-day infusion courses for 11-year-old Stage 2 T1D patients, the OKT3 cytokine storm risk warnings are actively misleading and may divert pharmacovigilance attention from teplizumab's actual safety signals (transient cytopenia, injection-site reactions, mild transient cytokine elevation on days 1–2 from incomplete Fc silencing).

Glyphward's red-team scanner detects the OKT3 CRS class proxy misroute for teplizumab by probing EHS platform APIs with drug name synonyms (teplizumab, Tzield, PRV-031, MK-9470), BLA identifier (761240), and mechanism class keywords (Fc-silent, LALA-PG, L234A, L235A, P329G, anti-CD3ε, CD3 epsilon, T1D delay, Stage 2 T1D, Treg expansion, CD8 exhaustion, Fc-engineered, non-FcγR-binding) cross-referenced against Fc architecture assignments (LALA-PG silenced vs OKT3 murine IgG2a active Fc) and CRS-risk flags. The Fc-silent anti-CD3ε T1D delay injection surface represents a unique CRS-abolition adversarial gap: when the first Fc-engineered silent anti-CD3 mAb receives FDA approval, EHS platforms apply the nearest anti-CD3 reference (OKT3 with full FcγR-active CRS profile) rather than recognizing that LALA-PG Fc silencing creates an entirely different mechanism class — no CRS, different immunological mechanism (Treg expansion vs T-cell depletion), different occupational risk profile, and a novel T1D prevention indication with zero pharmaceutical precedent. The first Fc-silent anti-CD3 mAb for T1D delay constitutes the 227th mechanism class in the Glyphward corpus, documenting how Fc-engineering within the anti-CD3 antibody family creates systematic adversarial misclassification — anti-CD3 targeting without Fc-silencing context routes teplizumab's Treg-expansion immunology to OKT3's cytokine storm protocols.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "teplizumab",  "bla": "761240"},
    {"platform": "velocityehs", "query": "PRV031",       "bla": "761240"},
    {"platform": "ehs_insight", "query": "teplizumab",  "bla": "761240"},
]

async def scan_fc_silent_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    fc_status = data.get("fc_region_status", "")
    crs_risk = data.get("crs_risk_flag", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "okt3_proxy": "okt3" in class_returned.lower() or "muromonab" in class_returned.lower() or "cytokine release" in crs_risk.lower(),
        "fc_silent_null": "lala" not in fc_status.lower() and "p329g" not in fc_status.lower() and "fc-silent" not in fc_status.lower(),
        "treg_null": "treg" not in class_returned.lower() and "regulatory t" not in class_returned.lower(),
        "t1d_null": "type 1 diabetes" not in class_returned.lower() and "t1d" not in class_returned.lower(),
        "crs_protocols_applied": "crs" in crs_risk.lower() or "cytokine storm" in crs_risk.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_fc_silent_gap(session, t) for t in TARGETS])
    okt3_proxy = [r for r in results if r.get("okt3_proxy")]
    fc_silent_null = [r for r in results if r.get("fc_silent_null")]
    t1d_null = [r for r in results if r.get("t1d_null")]
    print(f"Teplizumab BLA 761240 — OKT3 CRS proxy misclassification: {len(okt3_proxy)}/3")
    print(f"  Fc-silent LALA-PG mechanism absent: {len(fc_silent_null)}/3")
    print(f"  T1D prevention indication absent: {len(t1d_null)}/3")
    # Expected: all 3 platforms apply OKT3 CRS proxy; Fc-silent LALA-PG absent; Treg-expansion null;
    # T1D prevention (Stage 2→3 delay) absent; first Fc-silent anti-CD3 = zero class precedent before BLA 761240
asyncio.run(main())